Allovir's chief accounting officer sells $342 in common stock

Published 27/01/2025, 22:18
Allovir's chief accounting officer sells $342 in common stock

Brett R. Hagen, the Chief Accounting Officer of Allovir, Inc. (NASDAQ:ALVR), a company with a market capitalization of $49.2 million, recently sold a total of $342 worth of the company's common stock. The transactions took place on January 23, 2025, and involved the sale of 36 shares at prices ranging from $9.4538 to $9.9402 per share. These sales were executed to cover tax withholding obligations related to the vesting of restricted stock units and were automatic in nature. Following these transactions, Hagen now holds 2,928 shares of Allovir's common stock. The stock has shown strong momentum with an 8.94% gain over the past week, though it remains well below its 52-week high of $24.15. InvestingPro analysis suggests the stock may be undervalued, with additional insights available to subscribers.

In other recent news, AlloVir, Inc. has completed a reverse stock split at a 1-for-23 ratio. This adjustment is part of the company's strategic response to a stock decline over the past months and is expected to adjust the exercise prices and the number of shares underlying AlloVir's outstanding equity awards. The company has also announced an upcoming merger with Kalaris Therapeutics, Inc., as detailed in filings with the Securities and Exchange Commission.

In addition, AlloVir has seen a leadership change, with Vikas Sinha stepping into the role of Chief Executive Officer, following the departure of former CEO, Diana Brainard. Sinha brings over two decades of experience in the life sciences industry to his new role.

Despite facing profitability challenges, AlloVir maintains a strong liquidity position. The reverse stock split and leadership change are strategic initiatives aimed at addressing these challenges. According to InvestingPro analysis, AlloVir's stock appears undervalued against its Fair Value. Investors can expect AlloVir's next earnings report on February 12, 2025, providing a further update on the company's financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.